Literature DB >> 31578300

Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers.

Alexander J Cammack1, Nazem Atassi1, Theodore Hyman1, Leonard H van den Berg1, Matthew Harms1, Robert H Baloh1, Robert H Brown1, Michael A van Es1, Jan H Veldink1, Balint S de Vries1, Jeffrey D Rothstein1, Caroline Drain1, Jennifer Jockel-Balsarotti1, Amber Malcolm1, Sonia Boodram1, Amber Salter1, Nicholas Wightman1, Hong Yu1, Alexander V Sherman1, Thomas J Esparza1, Diane McKenna-Yasek1, Margaret A Owegi1, Catherine Douthwright1, Alexander McCampbell1, Toby Ferguson1, Carlos Cruchaga1, Merit Cudkowicz1, Timothy M Miller2.   

Abstract

OBJECTIVE: To define the natural history of the C9orf72 amyotrophic lateral sclerosis (C9ALS) patient population, develop disease biomarkers, and characterize patient pathologies.
METHODS: We prospectively collected clinical and demographic data from 116 symptomatic C9ALS and 12 non-amyotrophic lateral sclerosis (ALS) full expansion carriers across 7 institutions in the United States and the Netherlands. In addition, we collected blood samples for DNA repeat size assessment, CSF samples for biomarker identification, and autopsy samples for dipeptide repeat protein (DPR) size determination. Finally, we collected retrospective clinical data via chart review from 208 individuals with C9ALS and 450 individuals with singleton ALS.
RESULTS: The mean age at onset in the symptomatic prospective cohort was 57.9 ± 8.3 years, and median duration of survival after onset was 36.9 months. The monthly change was -1.8 ± 1.7 for ALS Functional Rating Scale-Revised and -1.4% ± 3.24% of predicted for slow vital capacity. In blood DNA, we found that G4C2 repeat size correlates positively with age. In CSF, we observed that concentrations of poly(GP) negatively correlate with DNA expansion size but do not correlate with measures of disease progression. Finally, we found that size of poly(GP) dipeptides in the brain can reach large sizes similar to that of their DNA repeat derivatives.
CONCLUSIONS: We present a thorough investigation of C9ALS natural history, providing the basis for C9ALS clinical trial design. We found that clinical features of this genetic subset are less variant than in singleton ALS. In addition, we identified important correlations of C9ALS patient pathologies with clinical and demographic data.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31578300      PMCID: PMC6946465          DOI: 10.1212/WNL.0000000000008359

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  50 in total

1.  Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study.

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Ellis Niemantsverdriet; Melissa E Murray; Michael G Heckman; Nancy N Diehl; Patricia H Brown; Matthew C Baker; NiCole A Finch; Peter O Bauer; Geidy Serrano; Thomas G Beach; Keith A Josephs; David S Knopman; Ronald C Petersen; Bradley F Boeve; Neill R Graff-Radford; Kevin B Boylan; Leonard Petrucelli; Dennis W Dickson; Rosa Rademakers
Journal:  Lancet Neurol       Date:  2013-09-05       Impact factor: 44.182

2.  Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS.

Authors:  Peter E A Ash; Kevin F Bieniek; Tania F Gendron; Thomas Caulfield; Wen-Lang Lin; Mariely Dejesus-Hernandez; Marka M van Blitterswijk; Karen Jansen-West; Joseph W Paul; Rosa Rademakers; Kevin B Boylan; Dennis W Dickson; Leonard Petrucelli
Journal:  Neuron       Date:  2013-02-12       Impact factor: 17.173

Review 3.  Mechanisms of trinucleotide repeat instability during human development.

Authors:  Cynthia T McMurray
Journal:  Nat Rev Genet       Date:  2010-11       Impact factor: 53.242

4.  Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations.

Authors:  Ian R Mackenzie; Thomas Arzberger; Elisabeth Kremmer; Dirk Troost; Stefan Lorenzl; Kohji Mori; Shih-Ming Weng; Christian Haass; Hans A Kretzschmar; Dieter Edbauer; Manuela Neumann
Journal:  Acta Neuropathol       Date:  2013-10-06       Impact factor: 17.088

5.  The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS.

Authors:  Kohji Mori; Shih-Ming Weng; Thomas Arzberger; Stephanie May; Kristin Rentzsch; Elisabeth Kremmer; Bettina Schmid; Hans A Kretzschmar; Marc Cruts; Christine Van Broeckhoven; Christian Haass; Dieter Edbauer
Journal:  Science       Date:  2013-02-07       Impact factor: 47.728

6.  Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases.

Authors:  Annemarie Hübers; Nicolai Marroquin; Birgit Schmoll; Stefan Vielhaber; Marlies Just; Benjamin Mayer; Josef Högel; Johannes Dorst; Thomas Mertens; Walter Just; Anna Aulitzky; Verena Wais; Albert C Ludolph; Christian Kubisch; Jochen H Weishaupt; Alexander E Volk
Journal:  Neurobiol Aging       Date:  2013-12-04       Impact factor: 4.673

7.  A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

Authors:  Alan E Renton; Elisa Majounie; Adrian Waite; Javier Simón-Sánchez; Sara Rollinson; J Raphael Gibbs; Jennifer C Schymick; Hannu Laaksovirta; John C van Swieten; Liisa Myllykangas; Hannu Kalimo; Anders Paetau; Yevgeniya Abramzon; Anne M Remes; Alice Kaganovich; Sonja W Scholz; Jamie Duckworth; Jinhui Ding; Daniel W Harmer; Dena G Hernandez; Janel O Johnson; Kin Mok; Mina Ryten; Danyah Trabzuni; Rita J Guerreiro; Richard W Orrell; James Neal; Alex Murray; Justin Pearson; Iris E Jansen; David Sondervan; Harro Seelaar; Derek Blake; Kate Young; Nicola Halliwell; Janis Bennion Callister; Greg Toulson; Anna Richardson; Alex Gerhard; Julie Snowden; David Mann; David Neary; Michael A Nalls; Terhi Peuralinna; Lilja Jansson; Veli-Matti Isoviita; Anna-Lotta Kaivorinne; Maarit Hölttä-Vuori; Elina Ikonen; Raimo Sulkava; Michael Benatar; Joanne Wuu; Adriano Chiò; Gabriella Restagno; Giuseppe Borghero; Mario Sabatelli; David Heckerman; Ekaterina Rogaeva; Lorne Zinman; Jeffrey D Rothstein; Michael Sendtner; Carsten Drepper; Evan E Eichler; Can Alkan; Ziedulla Abdullaev; Svetlana D Pack; Amalia Dutra; Evgenia Pak; John Hardy; Andrew Singleton; Nigel M Williams; Peter Heutink; Stuart Pickering-Brown; Huw R Morris; Pentti J Tienari; Bryan J Traynor
Journal:  Neuron       Date:  2011-09-21       Impact factor: 17.173

8.  Continuous and periodic expansion of CAG repeats in Huntington's disease R6/1 mice.

Authors:  Linda Møllersen; Alexander D Rowe; Elisabeth Larsen; Torbjørn Rognes; Arne Klungland
Journal:  PLoS Genet       Date:  2010-12-09       Impact factor: 5.917

9.  Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE.

Authors:  Ellen M Wijsman; Nathan D Pankratz; Yoonha Choi; Joseph H Rothstein; Kelley M Faber; Rong Cheng; Joseph H Lee; Thomas D Bird; David A Bennett; Ramon Diaz-Arrastia; Alison M Goate; Martin Farlow; Bernardino Ghetti; Robert A Sweet; Tatiana M Foroud; Richard Mayeux
Journal:  PLoS Genet       Date:  2011-02-17       Impact factor: 5.917

10.  A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats.

Authors:  Julie van der Zee; Ilse Gijselinck; Lubina Dillen; Tim Van Langenhove; Jessie Theuns; Sebastiaan Engelborghs; Stéphanie Philtjens; Mathieu Vandenbulcke; Kristel Sleegers; Anne Sieben; Veerle Bäumer; Githa Maes; Ellen Corsmit; Barbara Borroni; Alessandro Padovani; Silvana Archetti; Robert Perneczky; Janine Diehl-Schmid; Alexandre de Mendonça; Gabriel Miltenberger-Miltenyi; Sónia Pereira; José Pimentel; Benedetta Nacmias; Silvia Bagnoli; Sandro Sorbi; Caroline Graff; Huei-Hsin Chiang; Marie Westerlund; Raquel Sanchez-Valle; Albert Llado; Ellen Gelpi; Isabel Santana; Maria Rosário Almeida; Beatriz Santiago; Giovanni Frisoni; Orazio Zanetti; Cristian Bonvicini; Matthis Synofzik; Walter Maetzler; Jennifer Müller Vom Hagen; Ludger Schöls; Michael T Heneka; Frank Jessen; Radoslav Matej; Eva Parobkova; Gabor G Kovacs; Thomas Ströbel; Stayko Sarafov; Ivailo Tournev; Albena Jordanova; Adrian Danek; Thomas Arzberger; Gian Maria Fabrizi; Silvia Testi; Eric Salmon; Patrick Santens; Jean-Jacques Martin; Patrick Cras; Rik Vandenberghe; Peter Paul De Deyn; Marc Cruts; Christine Van Broeckhoven; Julie van der Zee; Ilse Gijselinck; Lubina Dillen; Tim Van Langenhove; Jessie Theuns; Stéphanie Philtjens; Kristel Sleegers; Veerle Bäumer; Githa Maes; Ellen Corsmit; Marc Cruts; Christine Van Broeckhoven; Julie van der Zee; Ilse Gijselinck; Lubina Dillen; Tim Van Langenhove; Stéphanie Philtjens; Jessie Theuns; Kristel Sleegers; Veerle Bäumer; Githa Maes; Marc Cruts; Christine Van Broeckhoven; Sebastiaan Engelborghs; Peter P De Deyn; Patrick Cras; Sebastiaan Engelborghs; Peter P De Deyn; Mathieu Vandenbulcke; Mathieu Vandenbulcke; Barbara Borroni; Alessandro Padovani; Silvana Archetti; Robert Perneczky; Janine Diehl-Schmid; Matthis Synofzik; Walter Maetzler; Jennifer Müller Vom Hagen; Ludger Schöls; Matthis Synofzik; Walter Maetzler; Jennifer Müller Vom Hagen; Ludger Schöls; Michael T Heneka; Frank Jessen; Alfredo Ramirez; Delia Kurzwelly; Carmen Sachtleben; Wolfgang Mairer; Alexandre de Mendonça; Gabriel Miltenberger-Miltenyi; Sónia Pereira; Clara Firmo; José Pimentel; Raquel Sanchez-Valle; Albert Llado; Anna Antonell; Jose Molinuevo; Ellen Gelpi; Caroline Graff; Huei-Hsin Chiang; Marie Westerlund; Caroline Graff; Anne Kinhult Ståhlbom; Håkan Thonberg; Inger Nennesmo; Anne Börjesson-Hanson; Benedetta Nacmias; Silvia Bagnoli; Sandro Sorbi; Valentina Bessi; Irene Piaceri; Isabel Santana; Beatriz Santiago; Isabel Santana; Maria Helena Ribeiro; Maria Rosário Almeida; Catarina Oliveira; João Massano; Carolina Garret; Paula Pires; Giovanni Frisoni; Orazio Zanetti; Cristian Bonvicini; Stayko Sarafov; Ivailo Tournev; Albena Jordanova; Ivailo Tournev; Gabor G Kovacs; Thomas Ströbel; Michael T Heneka; Frank Jessen; Alfredo Ramirez; Delia Kurzwelly; Carmen Sachtleben; Wolfgang Mairer; Frank Jessen; Radoslav Matej; Eva Parobkova; Adrian Danel; Thomas Arzberger; Gian Maria Fabrizi; Silvia Testi; Sergio Ferrari; Tiziana Cavallaro; Eric Salmon; Patrick Santens; Patrick Cras
Journal:  Hum Mutat       Date:  2013-01-04       Impact factor: 4.878

View more
  9 in total

Review 1.  Antisense Oligonucleotides for the Study and Treatment of ALS.

Authors:  Benjamin D Boros; Kathleen M Schoch; Collin J Kreple; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2022-06-02       Impact factor: 6.088

2.  Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of C9orf72-associated ALS or FTD.

Authors:  Yuanjing Liu; Amy Andreucci; Naoki Iwamoto; Yuan Yin; Hailin Yang; Fangjun Liu; Alexey Bulychev; Xiao Shelley Hu; Xuena Lin; Sarah Lamore; Saurabh Patil; Susovan Mohapatra; Erin Purcell-Estabrook; Kristin Taborn; Elena Dale; Chandra Vargeese
Journal:  Mol Ther Nucleic Acids       Date:  2022-04-20       Impact factor: 10.183

3.  Poly(GR) and poly(GA) in cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD.

Authors:  Gopinath Krishnan; Denitza Raitcheva; Daniel Bartlett; Mercedes Prudencio; Diane M McKenna-Yasek; Catherine Douthwright; Björn E Oskarsson; Shafeeq Ladha; Oliver D King; Sami J Barmada; Timothy M Miller; Robert Bowser; Jonathan K Watts; Leonard Petrucelli; Robert H Brown; Mark W Kankel; Fen-Biao Gao
Journal:  Nat Commun       Date:  2022-05-19       Impact factor: 17.694

Review 4.  Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.

Authors:  Flavien Bizot; Adeline Vulin; Aurélie Goyenvalle
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

Review 5.  Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions.

Authors:  Emma L van der Ende; Jazmyne L Jackson; Marka van Blitterswijk; John C Van Swieten; Adrianna White; Harro Seelaar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-01-15       Impact factor: 10.154

Review 6.  Glial Cell Dysfunction in C9orf72-Related Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Authors:  Mehdi Ghasemi; Kiandokht Keyhanian; Catherine Douthwright
Journal:  Cells       Date:  2021-01-28       Impact factor: 6.600

7.  Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis.

Authors:  Wei-Ming Su; Xiao-Jing Gu; Qing-Qing Duan; Zheng Jiang; Xia Gao; Hui-Fang Shang; Yong-Ping Chen
Journal:  BMC Med       Date:  2022-06-27       Impact factor: 11.150

Review 8.  Gene Therapy in Amyotrophic Lateral Sclerosis.

Authors:  Ton Fang; Goun Je; Peter Pacut; Kiandokht Keyhanian; Jeff Gao; Mehdi Ghasemi
Journal:  Cells       Date:  2022-06-29       Impact factor: 7.666

9.  Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications.

Authors:  Dario Saracino; Karim Dorgham; Agnès Camuzat; Daisy Rinaldi; Armelle Rametti-Lacroux; Marion Houot; Fabienne Clot; Philippe Martin-Hardy; Ludmila Jornea; Carole Azuar; Raffaella Migliaccio; Florence Pasquier; Philippe Couratier; Sophie Auriacombe; Mathilde Sauvée; Claire Boutoleau-Bretonnière; Jérémie Pariente; Mira Didic; Didier Hannequin; David Wallon; Olivier Colliot; Bruno Dubois; Alexis Brice; Richard Levy; Sylvie Forlani; Isabelle Le Ber
Journal:  J Neurol Neurosurg Psychiatry       Date:  2021-08-04       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.